9amHealth

The founding team consists of Frank Westermann, Anton Kittelberger, Paul Geevarghese, and Bernhard Schandl, who were previously behind the successful diabetes management app mySugr, which was acquired by Roche in 2017. The personal experiences of co-founders and co-CEOs Frank Westermann and Anton Kittelberger, both of whom live with type 1 diabetes, inspired the creation of both mySugr and 9amHealth. Their journey fueled a mission to create a more patient-centric and accessible healthcare model.

9amHealth operates on a business-to-business-to-consumer (B2B2C) model, partnering with employers, health plans, and Pharmacy Benefit Managers (PBMs) to provide its services as a health benefit to their members and employees. The company also offers a direct-to-consumer subscription service. Its primary service is a virtual care platform that delivers personalized treatment plans, access to specialists (including endocrinologists and pharmacists), at-home lab testing, connected medical devices, and prescription medication delivery. The platform focuses on a step-therapy model, starting with lifestyle changes and generics before considering more expensive medications like GLP-1s when clinically appropriate.

The company has established partnerships with major pharmaceutical companies like Novo Nordisk and Eli Lilly, as well as entities like Mark Cuban Cost Plus Drug Company and SmithRx, to enhance access to affordable medications, including GLP-1s for obesity management. 9amHealth has demonstrated significant clinical outcomes, including reductions in A1c levels, body weight, and blood pressure. The company has successfully raised $29.8 million in funding across multiple rounds, with investors including 7Wire Ventures, Cigna Ventures, Founders Fund, and Leaps by Bayer.